Skip to content
glp1.howSign in

Mental & Social Health

GLP-1 medications and anxiety: what the evidence shows, and what to watch

Do GLP-1 medications cause anxiety? Large trial data say no overall increase: a 2026 meta-analysis of 86 randomized trials found no link, and the FDA's January 2026 review of 91 trials found no rise in anxiety or other psychiatric events. People still vary. Most stay stable, some feel calmer, and a minority develop new or worse anxiety. It is not a treatment for anxiety. This guide covers the evidence, what to monitor, and when to get help.

By the glp1.how editorial teamReviewed 4 min read

Evidence-backed

Does a GLP-1 calm anxiety or cause it? For most people, neither. The largest data sets find no overall increase. On January 13, 2026, the FDA reported a meta-analysis of 91 placebo-controlled trials with 107,910 patients that showed no increased risk of suicidal thoughts or behavior "or for other relevant psychiatric adverse events such as anxiety, depression, irritability, or psychosis," and asked for the suicidal-ideation warning to come off the Saxenda, Wegovy and Zepbound labels (FDA Drug Safety Communication (external link)). As of September 2026, the Wegovy prescribing information lists that warning as removed in February 2026. A separate 2026 meta-analysis of 86 randomized trials found no link with anxiety (risk ratio 0.92, 95% CI 0.72–1.19) (Han et al., Diabetes, Obesity and Metabolism, 2026, DOI (external link)).

Individual experience still varies. In a 2026 chart review of people on GLP-1 medications, about 78% of those with generalized anxiety disorder stayed stable, while new-onset anxiety appeared in a minority (Sa et al., Journal of Psychiatric Research, 2026, DOI (external link)). Most people are unchanged, some feel calmer, and a few feel worse. It makes sense to notice which one you are.

Why some people feel calmer

  • If blood-sugar swings were feeding your anxiety, steadier blood sugar can take the edge off.
  • When "food noise" and the constant negotiation with food go quiet, some people describe a calmer baseline.
  • In animal models of diabetes, semaglutide reduced anxiety- and depression-like behavior through anti-inflammatory pathways in the brain (Piątkowska-Chmiel et al., Cellular and Molecular Neurobiology, 2025, DOI (external link)). That was in mice. In people, a systematic review found semaglutide improved anxiety scores in one comparison, but the review's overall verdict was mixed (Meshkat et al., Brain and Behavior, 2025, DOI (external link)).

Why some people feel worse

A large pharmacovigilance study of the WHO's adverse-event reports found a modest increase in reported anxiety with semaglutide (reporting odds ratio about 1.26). It found larger signals for depressed mood and suicidality with semaglutide, and eating-disorder terms signaled with all three GLP-1s studied (dulaglutide, liraglutide and semaglutide). Apart from those, there was no overall rise in psychiatric reporting. These are voluntary reports, so they can't show how often anxiety happens or prove the drug caused it (Nishida et al., Clinical Nutrition, 2025, DOI (external link)). The randomized-trial data above are the stronger evidence.

In the 2026 chart review, new anxiety did emerge months into treatment in a minority of people, about 9% (Sa et al., Journal of Psychiatric Research, 2026, DOI (external link)).

Fast body change, shifting relationships and health worry can also stir up anxiety of their own, separate from any direct drug effect.

People describe both directions in their own words. A peer-reviewed study of Reddit, YouTube and TikTok posts found anxiety mentioned hundreds of times (353 matches), with weight loss linked to both better and worse mood and anxiety (Arillotta et al., Brain Sciences, 2023, DOI (external link)).

Is a GLP-1 a treatment for anxiety?

No. The biology is plausible, but the clinical evidence is mixed and inconclusive. In the systematic review, only a minority of randomized trials showed a significant psychiatric benefit, and most showed none (Meshkat et al., Brain and Behavior, 2025, DOI (external link)). A broad review treats GLP-1 use in mental health as an unsettled research question (De Giorgi et al., Nature Mental Health, 2025, DOI (external link)). Don't skip anxiety treatment that works because you're on a GLP-1, and don't start one for anxiety.

What to watch, and what to do

You can't predict which way you'll go, so watch and act:

  • Track your mood as well as the scale. A one-line daily note on anxiety and mood makes a real change easy to spot.
  • Check the physical causes first. New anxiety on a GLP-1 can be driven by low blood sugar (mainly if you also take insulin or a sulfonylurea; a GLP-1 on its own rarely causes it), dehydration, under-eating, or poor sleep. Fixing those can fix the feeling.
  • Tell your prescriber promptly about new or worsening anxiety, hopelessness, or thoughts of self-harm. The FDA still advises patients to report "new or worsening depression, suicidal thoughts, or any unusual changes in mood or behavior," and it may factor into dose or drug decisions.
  • Get support for the emotional load. A therapist can help with the anxiety that body change and health worry bring up. Our guide on getting mental health support while on a GLP-1 covers finding one. The same mood-tracking habit helps if you also have ADHD on a GLP-1.
  • In a crisis, don't wait. Call or text 988 (Suicide & Crisis Lifeline, US), or text HOME to 741741 (Crisis Text Line). Call 911 for immediate danger.

This article is general education, not medical or mental-health advice, and it is not a crisis service. If you're in crisis, use the resources above. Discuss any mood or anxiety changes with your prescriber or a licensed mental-health professional. Research findings above are attributed to PubMed-indexed articles with DOI links.

anxietymental-healthmoodside-effectsmonitoringmental-social-health

Common questions

Questions people often ask about this topic.

  • Does a GLP-1 cause anxiety or help it?

    For most people, neither. A 2026 meta-analysis of 86 randomized trials found no link between GLP-1s and anxiety, and the FDA's January 2026 review of 91 trials found no increase in anxiety or other relevant psychiatric events. In a 2026 chart review, roughly 78% of people with generalized anxiety stayed stable on a GLP-1. Some feel calmer (steadier blood sugar, quieter food noise) and a minority develop new or worse anxiety. Drug-safety report databases show a small anxiety signal with semaglutide, which is a reason to keep an eye on your mood without panicking.

  • Can I take a GLP-1 to treat my anxiety?

    No, it isn't an anxiety treatment. The biology is plausible, but the clinical evidence is mixed and inconclusive: in a systematic review only a minority of randomized trials showed a psychiatric benefit and most showed none. Don't skip anxiety care that works because you're on a GLP-1, and don't start one for anxiety. If anxiety is your main concern, talk to a mental-health professional.

  • Why might I feel more anxious after starting a GLP-1?

    New anxiety on a GLP-1 can be driven by physical causes: low blood sugar (mainly if you also take insulin or a sulfonylurea; a GLP-1 on its own rarely causes it), dehydration, under-eating, or poor sleep. Rapid body change and health worry can stir up real anxiety too. There's also a small reporting signal in drug-safety databases, though large trial analyses don't show an overall increase. Rule out the physical causes first, and tell your prescriber about new or worsening anxiety.

  • What should I do if my mood changes on a GLP-1?

    Track your mood as deliberately as your weight. A one-line daily note makes a real change easy to spot. Check the physical basics (blood sugar, hydration, eating, sleep). Tell your prescriber promptly about new or worsening anxiety, hopelessness, or thoughts of self-harm, since it may factor into dose or drug decisions, and consider a therapist for the emotional load of body change.

  • When should I get urgent help?

    If you have thoughts of harming yourself or you're in crisis, reach out now: call or text 988 for the Suicide & Crisis Lifeline (US), or text HOME to 741741 for the Crisis Text Line. Call 911 or go to the nearest emergency room if someone is in immediate danger. This article is general education, not a crisis service, so please use these resources if you need them.

Evidence: For & Against

Both sides of the topic, so you can weigh the evidence yourself.

Supporting1

Challenging3

Mixed findings4

Revision history

Updated 9 times since Sep 2, 2026 · show changes
  1. v10

    Common questions revised

  2. v9

    Body revised

  3. v8

    Evidence sources 6 → 8

  4. v7

    Common questions revised

  5. v6

    Summary rewritten; Body revised

  6. v5

    Body revised

  7. v4

    Common questions revised

  8. v3

    Body revised

  9. v2

    Body revised

  10. v1

    Change tracking began

Related guides

  • GLP-1 medications and depression: what the evidence shows, and what to watch · Do GLP-1 medications cause depression? The best evidence says no increase in the randomized trials, and in January 2026 the FDA asked for the suicidal-ideation warning to come off the Saxenda, Wegovy and Zepbound labels. Some real-world studies still find a small depression signal, depending on what the drug is compared with, and the months after stopping deserve attention. The drug isn't a depression treatment either. This guide covers the evidence on both sides, what to watch, and when to get help.
  • Getting mental health support while on a GLP-1: finding a therapist and the challenges to name · Losing weight on a GLP-1 changes more than your body. Appetite, self-image, coping habits, and how others treat you can all shift, sometimes faster than your mind catches up. This practical guide covers the mental-health challenges people commonly face on these medications, the kinds of professionals who can help, how to find and afford one, and the crisis resources to keep close.
  • GLP-1 medications and ADHD: what to know if you have both · ADHD and obesity often go together, so a meaningful number of people on a GLP-1 also have ADHD, and some take a stimulant. There are no trials of GLP-1s as an ADHD treatment, and they shouldn't be used as one. If you have both, three practical things matter: combining two appetite suppressants safely, the overlap between ADHD and eating, and the adherence hurdle a weekly injection poses when you have ADHD.
  • GLP-1s and a history of disordered eating: what the evidence says about safety · If you have a history of an eating disorder, or are living with one, a medication that suppresses appetite raises real questions. This guide covers what the early, mixed evidence shows about GLP-1 safety, why an active restrictive disorder is a different situation, and why the decision belongs with a treatment team that includes a mental-health professional.
  • "Taking a GLP-1 is cheating": where the myth comes from, and what the evidence says · "That's cheating" is something many GLP-1 users hear, and sometimes tell themselves. It rests on the belief that weight is a test of willpower and medication is the easy way out. This guide covers what the science of weight regulation shows, where the myth comes from, why it spreads, and how to respond to it.
  • Body-image lag after weight loss vs. body dysmorphia: how to tell the difference · After losing weight on a GLP-1, many people still 'feel' like their old body because the mind lags behind the mirror. That lag, nicknamed "phantom fat" or "ghost fat," is common and usually eases. Body dysmorphic disorder is different: a persistent, distorted preoccupation with appearance that needs professional care. This guide explains how to tell them apart, what helps your body image catch up, and where to get help.

Related terms

  • Zepbound · Eli Lilly's brand name for injectable tirzepatide, FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.
  • Saxenda · A brand of liraglutide, a daily-injection GLP-1 receptor agonist approved for chronic weight management and made by Novo Nordisk.
  • GLP-1 · A gut hormone (glucagon-like peptide-1) that stimulates insulin release, slows digestion, and reduces appetite; the target of drugs like semaglutide and liraglutide.
  • Wegovy · Novo Nordisk's brand name for semaglutide (weekly injection or, since December 2025, a daily pill), FDA-approved for chronic weight management and heart-risk reduction, and as an injection for MASH liver disease.
  • Generalized anxiety disorder (GAD) · A mental health condition marked by persistent, excessive, hard-to-control worry about many things over months, often with restlessness, tension, and poor sleep.
  • Food noise · A colloquial term for persistent, intrusive thoughts about food — commonly reported to diminish significantly on GLP-1 medications.
  • Semaglutide · A GLP-1 receptor agonist medication made by Novo Nordisk, sold under the brand names Ozempic (type 2 diabetes) and Wegovy (weight management), each as an injection or a pill.
  • Pharmacovigilance · The science and practice of detecting, assessing, and preventing adverse effects of medications once they are in real-world use, after clinical trials end.

Was this helpful?

Improve this page